Advanced autofluorescence reveals cellular pigment reservoirs with therapeutic potential at the Heidelberg 2025 International ...

Improved axial resolution allows clearer visualization of early atrophic changes, including iRORA vs cRORA differentiation, as shared at the Heidelberg 2025 International SPECTRALIS Symposium – And ...

A Bristol-based health technology start-up has trialled its "groundbreaking" sight-loss prevention technology as it becomes ...

1 AMD threatens distance as well as reading acuity ... In conclusion, the lesion size and the macular thickness decreased in the Avastin group. The OCT and FA showed that the macula turns dry and ...

Disorganization of retinal inner layers (DRIL) is likely an important biomarker signaling visual deterioration in patients with diabetic macular ischemia (DMI), and overall causes for functional ...

Age-related macular degeneration (AMD) is a major cause of blindness, especially in older adults. A key feature of early AMD ...

To evaluate long-term outcomes of anti-VEGF therapy for neovascular age-related macular degeneration (nAMD) in the Netherlands (NL), where bevacizumab is the mandated first-line drug, compared to high ...

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

The Scottish Medicines Consortium (SMC) has accepted Outlook Therapeutics’ Lytenava (bevacizumab gamma) for the treatment of ...

Patients with challenging diabetic macular edema may achieve anatomical gains and extended dosing intervals with bispecific faricimab.

Background/aims To determine whether a combination of baseline and change in spectral domain-optical coherence tomography (SD-OCT)-based biomarkers can predict visual outcomes in eyes with diabetic ...